vs
MAXCYTE, INC.（MXCT）与Inotiv, Inc.（NOTV）财务数据对比。点击上方公司名可切换其他公司
Inotiv, Inc.的季度营收约是MAXCYTE, INC.的25.3倍（$120.9M vs $4.8M）。Inotiv, Inc.净利率更高（-23.5% vs -200.5%，领先177.0%）。Inotiv, Inc.同比增速更快（0.8% vs -20.9%）。MAXCYTE, INC.自由现金流更多（$-2.9M vs $-10.6M）。过去两年Inotiv, Inc.的营收复合增速更高（0.8% vs -7.4%）
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
Inotiv公司是一家注册于美国印第安纳州的合同研究组织，总部位于该州拉斐特市。公司设有两大核心业务板块：发现与安全评估业务（DSA）以及研究模型与服务业务（RMS），可为小分子候选药物、生物治疗产品及生物医疗设备提供安全评估、分析、代谢研究、CMC及法规咨询等药物开发与环境科学相关服务。
MXCT vs NOTV — 直观对比
营收规模更大
NOTV
是对方的25.3倍
$4.8M
营收增速更快
NOTV
高出21.8%
-20.9%
净利率更高
NOTV
高出177.0%
-200.5%
自由现金流更多
MXCT
多$7.7M
$-10.6M
两年增速更快
NOTV
近两年复合增速
-7.4%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $4.8M | $120.9M |
| 净利润 | $-9.6M | $-28.4M |
| 毛利率 | — | — |
| 营业利润率 | -234.5% | -13.5% |
| 净利率 | -200.5% | -23.5% |
| 营收同比 | -20.9% | 0.8% |
| 净利润同比 | 9.4% | -2.7% |
| 每股收益（稀释后） | — | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MXCTNOTV
| Q4 25 | $4.8M | $120.9M | ||
| Q3 25 | $4.6M | $138.1M | ||
| Q2 25 | $5.8M | $130.7M | ||
| Q1 25 | $5.7M | $124.3M | ||
| Q4 24 | $6.1M | $119.9M | ||
| Q3 24 | $5.6M | $130.4M | ||
| Q2 24 | $5.0M | $105.8M | ||
| Q1 24 | $5.6M | $119.0M |
净利润MXCTNOTV
| Q4 25 | $-9.6M | $-28.4M | ||
| Q3 25 | $-12.4M | $-8.6M | ||
| Q2 25 | $-12.4M | $-17.6M | ||
| Q1 25 | $-10.3M | $-14.9M | ||
| Q4 24 | $-10.6M | $-27.6M | ||
| Q3 24 | $-11.6M | $-18.9M | ||
| Q2 24 | $-9.4M | $-26.1M | ||
| Q1 24 | $-9.5M | $-48.1M |
营业利润率MXCTNOTV
| Q4 25 | -234.5% | -13.5% | ||
| Q3 25 | -307.4% | -4.9% | ||
| Q2 25 | -244.3% | -4.3% | ||
| Q1 25 | -214.1% | -2.4% | ||
| Q4 24 | -213.1% | -12.9% | ||
| Q3 24 | -250.4% | -10.1% | ||
| Q2 24 | -241.0% | -19.6% | ||
| Q1 24 | -219.8% | -36.2% |
净利率MXCTNOTV
| Q4 25 | -200.5% | -23.5% | ||
| Q3 25 | -269.7% | -6.2% | ||
| Q2 25 | -212.2% | -13.5% | ||
| Q1 25 | -178.7% | -12.0% | ||
| Q4 24 | -175.0% | -23.0% | ||
| Q3 24 | -205.9% | -14.5% | ||
| Q2 24 | -188.8% | -24.7% | ||
| Q1 24 | -170.6% | -40.4% |
每股收益（稀释后）MXCTNOTV
| Q4 25 | — | $-0.83 | ||
| Q3 25 | $-0.12 | $-0.14 | ||
| Q2 25 | $-0.12 | $-0.51 | ||
| Q1 25 | — | $-0.44 | ||
| Q4 24 | — | $-1.02 | ||
| Q3 24 | $-0.11 | $-0.73 | ||
| Q2 24 | $-0.09 | $-1.00 | ||
| Q1 24 | — | $-1.86 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.0M | $12.7M |
| 总债务越低越好 | — | $405.8M |
| 股东权益账面价值 | $171.5M | $109.0M |
| 总资产 | $202.5M | $734.3M |
| 负债/权益比越低杠杆越低 | — | 3.72× |
8季度趋势，按日历期对齐
现金及短期投资MXCTNOTV
| Q4 25 | $103.0M | $12.7M | ||
| Q3 25 | $105.7M | $21.7M | ||
| Q2 25 | $126.6M | $6.2M | ||
| Q1 25 | $138.3M | $19.3M | ||
| Q4 24 | $154.5M | $38.0M | ||
| Q3 24 | $153.8M | $21.4M | ||
| Q2 24 | $157.3M | $14.4M | ||
| Q1 24 | $157.5M | $32.7M |
总债务MXCTNOTV
| Q4 25 | — | $405.8M | ||
| Q3 25 | — | $402.1M | ||
| Q2 25 | — | $396.5M | ||
| Q1 25 | — | $399.5M | ||
| Q4 24 | — | $396.0M | ||
| Q3 24 | — | $393.3M | ||
| Q2 24 | — | $382.4M | ||
| Q1 24 | — | $380.6M |
股东权益MXCTNOTV
| Q4 25 | $171.5M | $109.0M | ||
| Q3 25 | $180.3M | $136.0M | ||
| Q2 25 | $190.7M | $143.8M | ||
| Q1 25 | $199.4M | $157.7M | ||
| Q4 24 | $206.3M | $169.8M | ||
| Q3 24 | $213.3M | $170.5M | ||
| Q2 24 | $221.3M | $182.1M | ||
| Q1 24 | $226.4M | $207.2M |
总资产MXCTNOTV
| Q4 25 | $202.5M | $734.3M | ||
| Q3 25 | $213.5M | $771.1M | ||
| Q2 25 | $219.8M | $759.7M | ||
| Q1 25 | $230.0M | $766.0M | ||
| Q4 24 | $239.5M | $772.9M | ||
| Q3 24 | $248.6M | $781.4M | ||
| Q2 24 | $251.5M | $774.6M | ||
| Q1 24 | $257.9M | $815.4M |
负债/权益比MXCTNOTV
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 2.96× | ||
| Q2 25 | — | 2.76× | ||
| Q1 25 | — | 2.53× | ||
| Q4 24 | — | 2.33× | ||
| Q3 24 | — | 2.31× | ||
| Q2 24 | — | 2.10× | ||
| Q1 24 | — | 1.84× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.7M | $-5.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | $-10.6M |
| 自由现金流率自由现金流/营收 | -61.0% | -8.8% |
| 资本支出强度资本支出/营收 | 4.8% | 4.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-36.2M | $-28.7M |
8季度趋势，按日历期对齐
经营现金流MXCTNOTV
| Q4 25 | $-2.7M | $-5.4M | ||
| Q3 25 | $-7.5M | $14.3M | ||
| Q2 25 | $-9.9M | $-7.4M | ||
| Q1 25 | $-14.4M | $-12.8M | ||
| Q4 24 | $-7.8M | $-4.5M | ||
| Q3 24 | $-4.4M | $-2.4M | ||
| Q2 24 | $-4.8M | $-14.8M | ||
| Q1 24 | $-10.6M | $16.9M |
自由现金流MXCTNOTV
| Q4 25 | $-2.9M | $-10.6M | ||
| Q3 25 | $-7.8M | $11.6M | ||
| Q2 25 | $-10.4M | $-11.5M | ||
| Q1 25 | $-15.1M | $-18.3M | ||
| Q4 24 | $-8.0M | $-9.0M | ||
| Q3 24 | $-4.8M | $-7.7M | ||
| Q2 24 | $-5.1M | $-19.2M | ||
| Q1 24 | $-11.4M | $9.9M |
自由现金流率MXCTNOTV
| Q4 25 | -61.0% | -8.8% | ||
| Q3 25 | -168.5% | 8.4% | ||
| Q2 25 | -179.2% | -8.8% | ||
| Q1 25 | -262.3% | -14.7% | ||
| Q4 24 | -131.6% | -7.5% | ||
| Q3 24 | -85.5% | -5.9% | ||
| Q2 24 | -103.3% | -18.2% | ||
| Q1 24 | -203.6% | 8.3% |
资本支出强度MXCTNOTV
| Q4 25 | 4.8% | 4.3% | ||
| Q3 25 | 6.5% | 1.9% | ||
| Q2 25 | 10.0% | 3.1% | ||
| Q1 25 | 11.4% | 4.4% | ||
| Q4 24 | 2.4% | 3.7% | ||
| Q3 24 | 7.2% | 4.1% | ||
| Q2 24 | 5.9% | 4.2% | ||
| Q1 24 | 14.4% | 5.9% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MXCT
暂无分部数据
NOTV
| Research Models And Services Segment | $72.9M | 60% |
| Discovery And Safety Assessment Segment | $48.0M | 40% |
